Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers

American Journal of Pathology

Volumn 177, Issue 4, 2010, Pages 2034-2045

  Rodriguez Acebes, Sara ^a   Proctor, Ian ^b   Loddo, Marco ^a   Wollenschlaeger, Alex ^a   Rashid, Mohammed ^b   Falzon, Mary ^b   Prevost, A Toby ^b,d   Sainsbury, Richard ^c   Stoeber, Kai ^a,b   Williams, Gareth H ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CELL CYCLE PROTEIN CDC7; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MUTANT PROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER CELL CULTURE; CDC7 GENE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA REPLICATION; FEMALE; GENE; GENE TARGETING; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION;

EID: 77957341219     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.100421     Document Type: Article

References (43)

1. Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T: The lifetime risk of developing breast cancer. J Natl Cancer Inst 1993, 85:892-897
2. Miles DW: Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer. Breast Cancer Res 2009, 11:208
3. La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, Levi F: Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 2010, 21:1323-1360
4. Petrelli F, Cabiddu M, Cazzaniga ME, Cremonesi M, Barni S: Targeted therapies for the treatment of breast cancer in the post-trastuzumab era. Oncologist 2008, 13:373-381
5. Di Cosimo S, Baselga J: Targeted therapies in breast cancer: where are we now? Eur J Cancer 2008, 44:2781-2790
6. Hortobagyi GN: Trastuzumab in the treatment of breast cancer. N Engl J Med 2005, 353:1734-1736
7. Johnston SR: Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists. Int J Gynecol Cancer 2006, 16(Suppl 2):543-548
8. Williams GH, Stoeber K: Cell cycle markers in clinical oncology. Curr Opin Cell Biol 2007, 19:672-679
9. Swords R, Mahalingam D, O'Dwyer M, Santocanale C, Kelly K, Carew J, Giles F: Cdc7 kinase - a new target for drug development. Eur J Cancer 2010, 46:33-40
10. Machida YJ, Hamlin JL, Dutta A: Right place, right time, and only once: replication initiation in metazoans. Cell 2005, 123:13-24
11. Remus D, Diffley JF: Eukaryotic DNA replication control: lock and load, then fire. Curr Opin Cell Biol 2009, 21:771-777
12. Masai H, You Z, Arai K: Control of DNA replication: regulation and activation of eukaryotic replicative helicase. MCM IUBMB Life 2005, 57:323-335
13. Montagnoli A, Tenca P, Sola F, Carpani D, Brotherton D, Albanese C, Santocanale C: Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells. Cancer Res 2004, 64:7110-7116
14. Blow JJ, Gillespie PJ: Replication licensing and cancer-a fatal entanglement? Nat Rev Cancer 2008, 8:799-806
15. Loddo M, Kingsbury SR, Rashid M, Proctor I, Holt C, Young J, El-Sheikh S, Falzon M, Eward KL, Prevost T, Sainsbury R, Stoeber K, Williams GH: Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. Br J Cancer 2009, 100:959-970
16. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein LP, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874
17. Calza S, Hall P, Auer G, Bjohle J, Klaar S, Kronenwett U, Liu ET, Miller L, Ploner A, Smeds J, Bergh J, Pawitan Y: Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 2006, 8:R34
18. Tan DS, Marchio C, Jones RL, Savage K, Smith IE, Dowsett M, Reis-Filho JS: Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008, 111:27-44
19. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502
20. Bloom HJ, Richardson WW: Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957, 11:359-377
21. Rampaul RS, Pinder SE, Elston CW, Ellis IO: Prognostic and predictive factors in primary breast cancer and their role in patient management: the Nottingham Breast Team. Eur J Surg Oncol 2001, 27:229-238
22. Wharton SB, Hibberd S, Eward KL, Crimmins D, Jellinek DA, Levy D, Stoeber K, Williams GH: DNA replication licensing and cell cycle kinetics of oligodendroglial tumours. Br J Cancer 2004, 91:262-269
23. Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths DF, Williams GH: Mcm2. Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res 2005, 11:2510-2517
24. Kulkarni AA, Loddo M, Leo E, Rashid M, Eward KL, Fanshawe TR, Butcher J, Frost A, Ledermann JA, Williams GH, Stoeber K: DNA replication licensing factors and aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma. Clin Cancer Res 2007, 13:6153-6161
25. Shetty A, Loddo M, Fanshawe T, Prevost AT, Sainsbury R, Williams GH, Stoeber K: DNA replication licensing and cell cycle kinetics of normal and neoplastic breast. Br J Cancer 2005, 93:1295-1300
26. Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17:1474-1481
27. Haroske G, Giroud F, Reith A, Bocking A: 1997 ESACP consensus report on diagnostic DNA image cytometry. Part I: basic considerations and recommendations for preparation, measurement and interpretation European Society for Analytical Cellular Pathology. Anal Cell Pathol 1998, 17:189-200
28. Eward KL, Obermann EC, Shreeram S, Loddo M, Fanshawe T, Williams C, Jung HI, Prevost AT, Blow JJ, Stoeber K, Williams GH: DNA replication licensing in somatic and germ cells. J Cell Sci 2004, 117:5875-5886
29. Kulkarni AA, Kingsbury SR, Tudzarova S, Hong HK, Loddo M, Rashid M, Rodriguez-Acebes S, Prevost AT, Ledermann JA, Stoeber K, Williams GH: Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma. Clin Cancer Res 2009, 15:2417-2425
30. Seiler JA, Conti C, Syed A, Aladjem MI, Pommier Y: The intra-S-phase checkpoint affects both DNA replication initiation and elongation: singlecell and -DNA fiber analyses. Mol Cell Biol 2007, 27:5806-5818
31. Kingsbury SR, Loddo M, Fanshawe T, Obermann EC, Prevost AT, Stoeber K, Williams GH: Repression of DNA replication licensing in quiescence is independent of geminin and may define the cell cycle state of progenitor cells. Exp Cell Res 2005, 309:56-67
32. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527
33. Mackay A, Tamber N, Fenwick K, Iravani M, Grigoriadis A, Dexter T, Lord CJ, Reis-Filho JS, Ashworth A: A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. Breast Cancer Res Treat 2009, 118:481-498
34. Montagnoli A, Valsasina B, Brotherton D, Troiani S, Rainoldi S, Tenca P, Molinari A, Santocanale C: Identification of Mcm2 phosphorylation sites by S-phase-regulating kinases. J Biol Chem 2006, 281:10281-10290
35. Crosio C, Fimia GM, Loury R, Kimura M, Okano Y, Zhou H, Sen S, Allis CD, Sassone-Corsi P: Mitotic phosphorylation of histone H3: spatiotemporal regulation by mammalian Aurora kinases. Mol Cell Biol 2002, 22:874-885
36. Connell-Crowley L, Harper JW, Goodrich DW: Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell 1997, 8:287-301
37. Chi Y, Welcker M, Hizli AA, Posakony JJ, Aebersold R, Clurman BE: Identification of CDK2 substrates in human cell lysates. Genome Biol 2008, 9:R149
38. Johnston SR, Hickish T, Ellis P, Houston S, Kelland L, Dowsett M, Salter J, Michiels B, Perez-Ruixo JJ, Palmer P, Howes A: Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor. R115777, in advanced breast cancer J Clin Oncol 2003, 21:2492-2499
39. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, Eiermann W, Hess D, Morant R, Semiglazov V, Borner M, Salzberg M, Ostapenko V, Illiger HJ, Behringer D, Bardy-Bouxin N, Boni J, Kong S, Cincotta M, Moore L: Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005, 23:5314-5322
40. Arpino G, Laucirica R, Elledge RM: Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med 2005, 143:446-457
41. Nofech-Mozes S, Spayne J, Rakovitch E, Hanna W: Prognostic and predictive molecular markers in DCIS: a review. Adv Anat Pathol 2005, 12:256-264
42. Meijnen P, Peterse JL, Antonini N, Rutgers EJ, van de Vijver MJ: Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br J Cancer 2008, 98:137-142
43. Wiechmann L, Kuerer HM: The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer 2008, 112:2130-2142